12
Participants
Start Date
February 22, 2021
Primary Completion Date
February 28, 2022
Study Completion Date
October 31, 2022
Dapagliflozin 10 MG [Farxiga]
4-Week, double-blind, once daily oral 10mg dapagliflozin
REMD-477
4-Week, double-blind, once weekly subcutaneous injection with 35mg REMD-477 in 1mL solution.
Placebo
4-Week, double-blind, once weekly subcutaneous injection with placebo in 1mL solution.
UC San Diego Altman Clinical & Translational Research Institute, La Jolla
Collaborators (1)
REMD Biotherapeutics, Inc.
INDUSTRY
Juvenile Diabetes Research Foundation
OTHER
The Leona M. and Harry B. Helmsley Charitable Trust
OTHER
University of California, San Diego
OTHER